Ciprofloxacin
Brand names: Cipro · Active ingredient: Ciprofloxacin Hydrochloride
In short: Ciprofloxacin is indicated in adult patients for treatment of skin and skin structure infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa,methi
What is Ciprofloxacin used for?
Ciprofloxacin is indicated in adult patients for treatment of skin and skin structure infections caused by
Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa,methicillin-susceptible
Staphylococcus aureus,methicillin-susceptible
Staphylococcus epidermidis,or
Streptococcus pyogenes.
Ciprofloxacin is indicated in adult patients for treatment of bone and joint infections caused by
Enterobacter cloacae, Serratia marcescens,or
Pseudomonas aeruginosa.
Ciprofloxacin is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by
Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae,or
Bacteroides fragilis.
Ciprofloxacin is indicated in adult patients for treatment of infectious diarrhea caused by
Escherichia coli(enterotoxigenic isolates),
Campylobacter jejuni, Shigella boydii
â€
,
Shigella dysenteriae, Shigella flexnerior
Shigella sonnei
â€
when antibacterial therapy is indicated.
â€
Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. …
âš Boxed warning (FDA's strongest warning)
Fluoroquinolones, including Ciprofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together
including:
Tendinitis and tendon rupture
Peripheral neuropathy
Central nervous system effects
Discontinue Ciprofloxacin immediately and avoid the use of fluoroquinolones, including Ciprofloxacin, in patients who experience any of these serious adverse reactions
.Fluoroquinolones, including Ciprofloxacin, may exacerbate muscle weakness in patients with myasthenia gravis. Avoid Ciprofloxacin in patients with known history of myasthenia gravis
.
Because fluoroquinolones, including Ciprofloxacin, have been associated with serious adverse reactions
, reserve Ciprofloxacin for use in patients who have no alternative treatment options for the following indications:
Acute exacerbation of chronic bronchitis
Acute uncomplicated cystitis
Acute sinusitis
Ciprofloxacin dosage
Ciprofloxacin Tablets should be administered orally as described in the appropriate Dosage Guidelines tables.
The determination of dosage and duration for any particular patient must take into consideration the severity and nature of the infection, the susceptibility of the causative microorganism, the integrity of the patient's host-defense mechanisms, and the status of renal and hepatic function. The determination of dosage and duration for any particular patient must take into consideration the severity and nature of the infection, the susceptibility of the causative microorganism, the integrity of the patient's host-defense mechanisms, and the status of renal and hepatic function.
1. Generally ciprofloxacin should be continued for at least 2 days after the signs and symptoms of infection have disappeared, except for inhalational anthrax (post-exposure). 1. Generally ciprofloxacin should be continued for at least 2 days after the signs and symptoms of infection have disappeared, except for inhalational anthrax (post-exposure).
2. Used in conjunction with metronidazole. 2. Used in conjunction with metronidazole.
3. Begin drug administration as soon as possible after suspected or confirmed exposure. 3. Begin drug administration as soon as possible after suspected or confirmed exposure.
Infection | Dose | Frequency | Usual Durations
1
Skin and Skin Structure | 500–750 mg | every 12 hours | 7 to 14 days
Bone and Joint | 500–750 mg | every 12 hours | 4 to 8 weeks
Complicated Intra–Abdominal
2 | 500 mg | every 12 hours | 7 to 14 days
Infectious Diarrhea | 500 mg | every 12 hours | 5 to 7 days
Typhoid Fever | 500 mg | every 12 hours | 10 days
Uncomplicated Urethral and
Cervical Gonococcal Infections | 250 mg | single dose | single dose
Inhalational anthrax (post-exposure)
3 | 500 mg | every 12 hours | 60 days
Plague
3 | 500–750 mg | every 12 hours | 14 days
Chronic Bacterial Prostatitis | 500 mg | every 12 hours | 28 days
Lower Respiratory Tract Infections | 500–750 mg | every 12 hours | 7 to 14 days
Urinary Tract Infections | 250–500 mg | every 12 hours | 7 to 14 days
Acute Uncomplicated Cystitis | 250 mg | every 12 hours | 3 days
Acute Sinusitis | 500 mg | every 12 hours | 10 days
Conversion of IV to Oral Dosing in Adults
Patients whose therapy is started with Ciprofloxacin IV may be switched to Ciprofloxacin Tablets or Oral Suspension when clinically indicated at the discretion of the physician (
Table 2)
. …
How to take Ciprofloxacin — instructions & advice from the label
Advise the patient to read the
FDA-approved patient labeling (Medication Guide)
Serious Adverse Reactions
Advise patients to stop taking Ciprofloxacin if they experience an adverse reaction and to call their healthcare provider for advice on completing the full course of treatment with another antibacterial drug.
Inform patients of the following serious adverse reactions that have been associated with Ciprofloxacin or other fluoroquinolone use:
Disabling and potentially irreversible serious adverse reactions that may occur together:Inform patients that disabling and potentially irreversible serious adverse reactions, including tendinitis and tendon rupture, peripheral neuropathies, and central nervous system effects, have been associated with use of Ciprofloxacin and may occur together in the same patient. Inform patients to stop taking Ciprofloxacin immediately if they experience an adverse reaction and to call their healthcare provider. …
Warnings & precautions
Do not take this medicine if: Ciprofloxacin is contraindicated in persons with a history of hypersensitivity to ciprofloxacin, any member of the quinolone class of antibacterials, or any of the product components
.
Concomitant administration with tizanidine is contraindicated
.
Fluoroquinolones, including Ciprofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions from different body systems that can occur together in the same patient. Commonly seen adverse reactions include tendinitis, tendon rupture, arthralgia, myalgia, peripheral neuropathy, and central nervous system effects (hallucinations, anxiety, depression, insomnia, severe headaches, and confusion). These reactions can occur within hours to weeks after starting Ciprofloxacin. Patients of any age or without pre-existing risk factors have experienced these adverse reactions
.
Discontinue Ciprofloxacin immediately at the first signs or symptoms of any serious adverse reaction. In addition, avoid the use of fluoroquinolones, including Ciprofloxacin, in patients who have experienced any of these serious adverse reactions associated with fluoroquinolones.
Fluoroquinolones, including Ciprofloxacin, have been associated with an increased risk of tendinitis and tendon rupture in all ages
. This adverse reaction most frequently involves the Achilles tendon, and has also been reported with the rotator cuff (the shoulder), the hand, the biceps, the thumb, and other tendons. Tendinitis or tendon rupture can occur, within hours or days of starting Ciprofloxacin, or as long as several months after completion of fluoroquinolone therapy. Tendinitis and tendon rupture can occur bilaterally. …
Ciprofloxacin side effects
The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling:
Disabling and Potentially Irreversible Serious Adverse Reactions
Tendinitis and Tendon Rupture
Peripheral Neuropathy
Central Nervous System Effects
Exacerbation of Myasthenia Gravis
Other Serious and Sometimes Fatal Adverse Reactions
Hypersensitivity Reactions
Hepatotoxicity
Serious Adverse Reactions with Concomitant Theophylline
Clostridium difficile-Associated Diarrhea
Prolongation of the QT Interval
Musculoskeletal Disorders in Pediatric Patients
Photosensitivity/Phototoxicity
Development of Drug Resistant Bacteria
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adult Patients
During clinical investigations with oral and parenteral Ciprofloxacin, 49,038 patients received courses of the drug.
The most frequently reported adverse reactions, from clinical trials of all formulations, all dosages, all drug-therapy durations, and for all indications of ciprofloxacin therapy were nausea (2.5%), diarrhea (1.6%), liver function tests abnormal (1.3%), vomiting (1%), and rash (1%). …
Drug interactions
Ciprofloxacin is an inhibitor of human cytochrome P450 1A2 (CYP1A2) mediated metabolism. Co-administration of Ciprofloxacin with other drugs primarily metabolized by CYP1A2 results in increased plasma concentrations of these drugs and could lead to clinically significant adverse events of the co-administered drug.
Drugs That are Affected by Ciprofloxacin
Drug(s) | Recommendation | Comments
Tizanidine | Contraindicated | Concomitant administration of tizanidine and Ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine
Theophylline | Avoid Use
(Plasma Exposure Likely to be Increased and Prolonged) | Concurrent administration of Ciprofloxacin with theophylline may result in increased risk of a patient developing central nervous system (CNS) or other adverse reactions. If concomitant use cannot be avoided, monitor serum levels of theophylline and adjust dosage as appropriate
.
Drugs Known to
Prolong QT Interval | Avoid Use | Ciprofloxacin may further prolong the QT interval in patients receiving drugs known to prolong the QT interval (for example, class IA or III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics)
[see Warnings and Precautions (
5.11
) and Use in
Specific Populations (
8.5
)]. …
About this medicine
Ciprofloxacin (Ciprofloxacin hydrochloride) Tablets are synthetic antimicrobial agents for oral administration. Ciprofloxacin hydrochloride, USP, a fluoroquinolone, is the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid. It is a faintly yellowish to light yellow crystalline substance with a molecular weight of 385.8. Its empirical formula is C
17H
18FN
3O
3•HCl•H
2O and its chemical structure is as follows:
Ciprofloxacin is 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid. Its empirical formula is C
17H
18FN
3O
3and its molecular weight is 331.4. It is a faintly yellowish to light yellow crystalline substance and its chemical structure is as follows:
Ciprofloxacin film-coated tablets are available in 250 mg, 500 mg and 750 mg (ciprofloxacin equivalent) strengths. Ciprofloxacin tablets are white to slightly yellowish. The inactive ingredients are Lactose Monohydrate, Magnesium Stearate, Sodium Starch Gylcolate, and Starch 1500 (Modified Corn Starch). …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 74e2dd24-5c6e-4dde-a2ab-f2d2e61734d8. Read the full official label on DailyMed.
Related medicines
Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin